PreprintArticleVersion 1Preserved in Portico This version is not peer-reviewed
Impact of the Main Pharmacological Option and Risk Factors for COVID-19 Disease Progression in Hospitalized Patients in Northern Italy: A Single-Center Retrospective Study
Version 1
: Received: 4 October 2023 / Approved: 5 October 2023 / Online: 5 October 2023 (06:20:11 CEST)
How to cite:
Bolla, C.; Penpa, S.; Sarchi, E.; Schimmenti, A.; Piceni, G.; Bertolotti, M.; Panzacchi, S.; Mandrioli, D.; Chichino, G.; Maconi, A. Impact of the Main Pharmacological Option and Risk Factors for COVID-19 Disease Progression in Hospitalized Patients in Northern Italy: A Single-Center Retrospective Study. Preprints2023, 2023100252. https://doi.org/10.20944/preprints202310.0252.v1
Bolla, C.; Penpa, S.; Sarchi, E.; Schimmenti, A.; Piceni, G.; Bertolotti, M.; Panzacchi, S.; Mandrioli, D.; Chichino, G.; Maconi, A. Impact of the Main Pharmacological Option and Risk Factors for COVID-19 Disease Progression in Hospitalized Patients in Northern Italy: A Single-Center Retrospective Study. Preprints 2023, 2023100252. https://doi.org/10.20944/preprints202310.0252.v1
Bolla, C.; Penpa, S.; Sarchi, E.; Schimmenti, A.; Piceni, G.; Bertolotti, M.; Panzacchi, S.; Mandrioli, D.; Chichino, G.; Maconi, A. Impact of the Main Pharmacological Option and Risk Factors for COVID-19 Disease Progression in Hospitalized Patients in Northern Italy: A Single-Center Retrospective Study. Preprints2023, 2023100252. https://doi.org/10.20944/preprints202310.0252.v1
APA Style
Bolla, C., Penpa, S., Sarchi, E., Schimmenti, A., Piceni, G., Bertolotti, M., Panzacchi, S., Mandrioli, D., Chichino, G., & Maconi, A. (2023). Impact of the Main Pharmacological Option and Risk Factors for COVID-19 Disease Progression in Hospitalized Patients in Northern Italy: A Single-Center Retrospective Study. Preprints. https://doi.org/10.20944/preprints202310.0252.v1
Chicago/Turabian Style
Bolla, C., Guido Chichino and Antonio Maconi. 2023 "Impact of the Main Pharmacological Option and Risk Factors for COVID-19 Disease Progression in Hospitalized Patients in Northern Italy: A Single-Center Retrospective Study" Preprints. https://doi.org/10.20944/preprints202310.0252.v1
Abstract
Severe Acute Respiratory Disease Syndrome Coronavirus 2 has caused a global pandemic. Monoclonal antibodies, antiviral therapy (Remdesivir) and immunomodulatory agents represent one of the most promising therapies to prevent disease progression and reduce the relative risk of severe COVID-19. The aim of this study was to evaluate the impact on the disease progression of the main pharmacological options approved for the patients admitted in hospital with acute COVID-19 infection, according to their vaccination status..
We conducted a study including adult patients with confirmed COVID-19 admitted to the Infectious Diseases Unit of Alessandria’s Hospital in Italy, from October 2021 to March 2022.
102 patients were included in the analysis. The mean age was 69.2 ±15.4 years, 66.7% were males. According to the internal hospital’s guidelines, 47.06% patients with mild to moderate disease were treated with mAbs, 45.10% were treated with Remdesivir, of which 10.78% received combination therapy with mAbs. The most frequently complications were pneumonia (18.63%), respiratory failure (15.68%) and acute respiratory distress syndrome (13.72%). The mean length of hospitalization was 13.42 (±10.90) days and the mortality rate was 11.76%.
The treatment with mAbs and immunomodulatory therapy for mild to moderate COVID-19 infection seem to be effective to improve the outcome reducing disease progression and mortality. C-reactive protein (CRP) and ferritin could be considered a good inflammatory marker of disease progression.
Medicine and Pharmacology, Medicine and Pharmacology
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
